Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

BACKGROUND: Tislelizumab plus chemotherapy improved overall survival compared to chemotherapy alone, while maintaining an acceptable level of safety. But it’s still unclear which strategy is the most cost-effective. The objective of the study was to compare the cost-effectiveness of tislelizumab plu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Chongchong, Wei, Jingxuan, Xu, Kai, Lin, Yingtao, Zhang, Lingli, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657759/
https://www.ncbi.nlm.nih.gov/pubmed/38024498
http://dx.doi.org/10.2147/RMHP.S436750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657759/
https://www.ncbi.nlm.nih.gov/pubmed/38024498
http://dx.doi.org/10.2147/RMHP.S436750

Ejemplares similares